Literature DB >> 10102355

Analysis of two chromosomal regions adjacent to genes for a type II polyketide synthase involved in the biosynthesis of the antitumor polyketide mithramycin in Streptomyces argillaceus.

L Prado1, F Lombó, A F Braña, C Méndez, J Rohr, J A Salas.   

Abstract

Mithramycin is an aromatic antitumour polyketide synthesized by Streptomyces argillaceus. Two chromosomal regions located upstream and downstream of the locus for the mithramycin type II polyketide synthase were cloned and sequenced. Analysis of the sequence revealed the presence of eight genes encoding three oxygenases (mtmOI, mtmOII and mtmOIII), three reductases (mtmTI, mtmTII and mtmTIII), a cyclase (mtm Y) and an acyl CoA ligase (mtmL). The three oxygenase genes were each inactivated by gene replacement. Inactivation of one of them (mtmOII) generated a non-producing mutant, while inactivation of the other two (mtmOl and mtmOIII) did not affect the biosynthesis of mithramycin. The mtmOII gene may code for an oxygenase responsible for the introduction of oxygen atoms at early steps in the biosynthesis of mithramycin leading to 4-demethylpremithramycinone. One of the reductases may be responsible for reductive cleavage of an intermediate from an enzyme and another for the reduction of a keto group in the side-chain of the mithramycin aglycon moiety. A hypothetical biosynthetic pathway showing in particular the involvement of oxygenase MtmOII and of various other gene products in mithramycin biosynthesis is proposed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102355     DOI: 10.1007/s004380050960

Source DB:  PubMed          Journal:  Mol Gen Genet        ISSN: 0026-8925


  11 in total

1.  Premithramycinone G, an early shunt product of the mithramycin biosynthetic pathway accumulated upon inactivation of oxygenase MtmOII.

Authors:  Mohamed S Abdelfattah; Jürgen Rohr
Journal:  Angew Chem Int Ed Engl       Date:  2006-08-25       Impact factor: 15.336

Review 2.  Epigenetic mechanisms of neurodegeneration in Huntington's disease.

Authors:  Junghee Lee; Yu Jin Hwang; Ki Yoon Kim; Neil W Kowall; Hoon Ryu
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 3.  Oxytetracycline biosynthesis.

Authors:  Lauren B Pickens; Yi Tang
Journal:  J Biol Chem       Date:  2010-06-03       Impact factor: 5.157

4.  Characterization of LnmO as a pathway-specific Crp/Fnr-type positive regulator for leinamycin biosynthesis in Streptomyces atroolivaceus and its application for titer improvement.

Authors:  Yong Huang; Dong Yang; Guohui Pan; Gong-Li Tang; Ben Shen
Journal:  Appl Microbiol Biotechnol       Date:  2016-10-05       Impact factor: 4.813

Review 5.  Biosynthesis of Oxytetracycline by Streptomyces rimosus:
Past, Present and Future Directions in the Development
of Tetracycline Antibiotics.

Authors:  Hrvoje Petković; Tadeja Lukežič; Jagoda Šušković
Journal:  Food Technol Biotechnol       Date:  2017-03       Impact factor: 3.918

6.  Engineered biosynthesis of a novel amidated polyketide, using the malonamyl-specific initiation module from the oxytetracycline polyketide synthase.

Authors:  Wenjun Zhang; Brian D Ames; Shiou-Chuan Tsai; Yi Tang
Journal:  Appl Environ Microbiol       Date:  2006-04       Impact factor: 4.792

7.  Ketopremithramycins and ketomithramycins, four new aureolic acid-type compounds obtained upon inactivation of two genes involved in the biosynthesis of the deoxysugar moieties of the antitumor drug mithramycin by Streptomyces argillaceus, reveal novel insights into post-PKS tailoring steps of the mithramycin biosynthetic pathway.

Authors:  Lily L Remsing; Jose Garcia-Bernardo; Ana Gonzalez; Eva Künzel; Uwe Rix; Alfredo F Braña; Daniel W Bearden; Carmen Méndez; Jose A Salas; Jürgen Rohr
Journal:  J Am Chem Soc       Date:  2002-02-27       Impact factor: 15.419

8.  Biochemical analysis of the biosynthetic pathway of an anticancer tetracycline SF2575.

Authors:  Lauren B Pickens; Woncheol Kim; Peng Wang; Hui Zhou; Kenji Watanabe; Shuichi Gomi; Yi Tang
Journal:  J Am Chem Soc       Date:  2009-12-09       Impact factor: 15.419

9.  Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity.

Authors:  Zhiliang Jia; Yong Gao; Liwei Wang; Qiang Li; Jun Zhang; Xiangdong Le; Daoyan Wei; James C Yao; David Z Chang; Suyun Huang; Keping Xie
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

10.  Multifunctional SEVA shuttle vectors for actinomycetes and Gram-negative bacteria.

Authors:  Coral García-Gutiérrez; Tomás Aparicio; Lucía Torres-Sánchez; Esteban Martínez-García; Víctor de Lorenzo; Claudio J Villar; Felipe Lombó
Journal:  Microbiologyopen       Date:  2020-03-14       Impact factor: 3.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.